Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in IntangiblesChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lexaria Bioscience (LEXX) Net Income (2017 - 2026)

Lexaria Bioscience's Net Income history spans 10 years, with the latest figure at -$1.5 million for Q1 2026.

  • Quarterly results put Net Income at -$1.5 million for Q1 2026, up 47.19% from a year ago — trailing twelve months through Feb 2026 was -$9.5 million (down 0.89% YoY), and the annual figure for FY2025 was -$11.9 million, down 106.97%.
  • Net Income for Q1 2026 was -$1.5 million at Lexaria Bioscience, up from -$1.6 million in the prior quarter.
  • In the past five years, Net Income ranged from a high of -$668006.0 in Q1 2024 to a low of -$3.8 million in Q2 2025.
  • The 5-year median for Net Income is -$1.7 million (2022), against an average of -$1.9 million.
  • The sharpest move saw Net Income plummeted 5694.69% in 2022, then soared 49.53% in 2024.
  • Year by year, Net Income stood at -$1.7 million in 2022, then soared by 33.24% to -$1.1 million in 2023, then crashed by 137.73% to -$2.7 million in 2024, then skyrocketed by 41.45% to -$1.6 million in 2025, then rose by 7.79% to -$1.5 million in 2026.
  • According to Business Quant data, Net Income over the past three periods came in at -$1.5 million, -$1.6 million, and -$2.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.